WuXi AppTec and Juno Therapeutics' immuno-oncology joint venture is reportedly seeking $250m to $300m in a Hong Kong offering.
JW Therapeutics, the China-based cancer therapy developer launched by biopharmaceutical companies Juno Therapeutics and WuXi AppTec has filed for an initial public offering on the Hong Kong Stock Exchange, Caixin Global reported today.
Earlier reports suggested the company is targeting $200m to $300m in the offering, and the sponsors for it are Goldman Sachs and UBS.
Founded in 2016 as a joint venture between WuXi AppTec and Juno Therapeutics, JW is working on immuno-oncology drugs that utilise engineered chimeric antigen…
